0
Abstract: Poster Presentations |

LUNG DEPOSITION OF QVAR (HFA134A-BDP) IN NEWBORN INFANTS WITH BRONCHOPULMONARY DYSPLASIA (BPD) FREE TO VIEW

Myrna B. Dolovich, *; David Millar, MB, BCh; Lori Sterling, RN; Rod Rhem, BSc; Andrew P. Bosco, BSc; Haresh Kirpalani, MB, BCh
Author and Funding Information

McMaster University, Hamilton, ON, Canada


Chest


Chest. 2005;128(4_MeetingAbstracts):351S. doi:10.1378/chest.128.4_MeetingAbstracts.351S
Text Size: A A A
Published online

Abstract

PURPOSE:  Aerosol delivery to ventilated newborns is known to be poor. CFC beclomethasone dipropionate (BDP) pMDI has been reformulated as an HFA134a solution (QVAR, 3M Pharmaceuticals, London, ON) with a demonstrably lower mass median aerodynamic diameter (MMAD) of 1.1 μm and geometric standard deviation (GSD) 2.5 than the CFC aerosol. We hypothesised that an aerosol with these properties would result in increased delivery to the peripheral lung with a greater total pulmonary deposition. Aim: To investigate the total pulmonary deposition following inhalation of radiolabelled HFA 134a BDP in ventilated neonates.

METHODS:  Data expressed as mean(sd). Eight ventilated neonates with BPD, 40.3 (10.9) days old at time of study, with a mean corrected age of 32.2 (1.65) weeks post-gestation) were enrolled. Babies weighed 823.5 (222.7)g at birth and 1182.9 (188.3)g at time of study. Vital signs were monitored throughout the study. One dose of radiolabelled BDP (186 (57)μCi in 47 (14)μg BDP) was given via a Neonatal Ventilator Aerosol Delivery System (NVADS, Trudell Medical Inc, London, ON), a tube spacer with low dead-space connectors to interface to the ventilator circuit. Posterior images of the lungs and lateral head were obtained over 10 min using a GE Starcam gamma camera. Tissue attenuation factors for each baby were obtained using a phantom.

RESULTS:  O2 saturation was unchanged during delivery of the aerosol (predose: 90.8 (5.2)%; dosing: 89.5 (5.1)%; post-dose: 91.6 (4.2)%). Most of the radiolabelled drug was captured in the NVADS (80.0 (13.1)%) and circuit tubing and connectors. Lung deposition was 1.27 (0.95)% of the recovered emitted dose ex-actuator or 8.63 ± 7.39% of the dose ex-spacer. These percentages translated into an average deposited lung dose of 0.6μg BDP.

CONCLUSION:  These values are similar to prior work with CFC formulations of salbutamol and appear to show no advantage in the total dose of HFA134a BDP delivered to these ventilated neonates.

CLINICAL IMPLICATIONS:  Clinical trials would need to be undertaken to determine if even this low deposition efficiency could provide a beneficial clinical outcome.

DISCLOSURE:  Myrna Dolovich, Grant monies (from industry related sources); Study funded by 3M Pharmaceuticals Canada.

Wednesday, November 2, 2003

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543